Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07896772). This is a study registration, not published results. Lead sponsor: Masaryk Memorial Cancer Institute. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 200 participants (ESTIMATED). Conditions: Breast Cancer. Primary outcome measures: Serum Anti-Müllerian Hormone (AMH) Levels , Baseline (At the time of blood sampling). Brief summary: This study aims to evaluate serum anti-Müllerian hormone (AMH) levels and complementary hormonal parameters, including follicle-stimulating hormone (FSH), estradiol, thyroid-stimulating hormone (TSH), and free thyroxine (fT4), in women with breast cancer and healthy female controls. The study will generate preliminary real-world data on AMH and related hormonal parameters and assess the feasibility of implementing AMH testing into routine clinical practice.